Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

被引：0
|
作者：
Jian Zhang
Nicholas P. McAndrew
Xiaojia Wang
Yiqun Du
Brian DiCarlo
Mei Wang
Kan Chen
Wenlei Yu
Xichun Hu
机构：
[1] Fudan University Shanghai Cancer Center,Phase I Clinical Trial Center
[2] Fudan University,Department of Oncology, Shanghai Medical College
[3] UCLA David Geffen School of Medicine,Division of Hematology/Oncology
[4] Zhejiang Cancer Hospital,Department of Medical Oncology
[5] Dizal Pharmaceutical,undefined
[6] Fudan University Shanghai Cancer Center,undefined
来源：
Breast Cancer Research | / 25卷
关键词：
HER2; Tyrosine kinase inhibitor; Blood–brain barrier; Breast cancer; Central nervous system metastases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 28 条
  • [21] VRN101396, a brain-permeable HER2 inhibitor, shows the anti-tumor activity in preclinical HER2-positive cancer models
    Jung, Hong-ryul
    Kim, Sunghwan
    Yoo, Jihye
    Park, Chan Mi
    Lee, Somi
    Lee, Hyoju
    Lee, Youngyi
    Park, Jinhee
    Seo, Kyungah
    Seo, Dong-Hyuk
    Ko, Eunhwa
    Son, Jung Beom
    Kim, Deakwon
    Choi, Hwan Geun
    Kim, Nam Doo
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Identification of a brain penetrant, highly selective phosphodiesterase 2A inhibitor clinical candidate for treating cognitive impairment: In vivo efficacy and human pharmacokinetic data
    Helal, Christopher J.
    Chappie, Thomas
    Humphrey, John
    Verhoest, Patrick
    Yang, Eddie
    Arnold, Eric
    Bundesmann, Mark
    Hou, Xinjun
    Kormos, Bethany
    Mente, Scot
    Kleiman, Robin
    Pandit, Jayvardhan
    Schmidt, Chris
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [23] Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
    Robichaux, Jacqulyne P.
    Elamin, Yasir Y.
    Tan, Zhi
    Carter, Brett W.
    Zhang, Shuxing
    Liu, Shengwu
    Li, Shuai
    Chen, Ting
    Poteete, Alissa
    Estrada-Bernal, Adriana
    Le, Anh T.
    Truini, Anna
    Nilsson, Monique B.
    Sun, Huiying
    Roarty, Emily
    Goldberg, Sarah B.
    Brahmer, Julie R.
    Altan, Mehmet
    Lu, Charles
    Papadimitrakopoulou, Vassiliki
    Politi, Katerina
    Doebele, Robert C.
    Wong, Kwok-Kin
    Heymach, John V.
    NATURE MEDICINE, 2018, 24 (05) : 638 - +
  • [24] Preclinical evaluation of eFT226, a potent and selective eIF4A inhibitor with anti-tumor activity in FGFR1,2 and HER2 driven cancers
    Thompson, Peggy A.
    Young, Nathan P.
    Gerson-Gurwitz, Adina
    Eam, Boreth
    Goel, Vikas
    Stumpf, Craig R.
    Chen, Joan
    Parker, Gregory S.
    Fish, Sarah
    Barrera, Maria
    Sung, Eric
    Staunton, Jocelyn
    Chiang, Gary G.
    Webster, Kevin R.
    CANCER RESEARCH, 2020, 80 (16)
  • [25] The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer
    Zou, Yue
    Dhar, Srijita
    Gallagher, Kirsten
    Buesking, Andrew
    Pawley, Sarah
    Holmes, Ryan
    Wu, Xiaowei
    Rohlfing, Katarina
    Wang, Min
    Rager, Joseph
    Emm, Tom
    Ruepp, Stefan
    Cowart, Miles
    Ni, Jing
    Zhao, Jean
    Ruggeri, Bruce
    Combs, Andrew
    Vaddi, Kris
    Geeganage, Sandy
    Juvekar, Ashish
    Lee, Sang Hyun
    Scherle, Peggy
    CANCER RESEARCH, 2023, 83 (07)
  • [26] A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+metastatic breast cancer (MBC)
    Jhaveri, Komal L.
    Hamilton, Erika Paige
    Miller, Kathy
    Roche, Maria
    Berger, Mark S.
    Winer, Eric P.
    Lin, Nancy U.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer (vol 24, pg 638, 2018)
    Robichaux, Jacqulyne P.
    Elamin, Yasir Y.
    Tan, Zhi
    Carter, Brett W.
    Zhang, Shuxing
    Liu, Shengwu
    Li, Shuai
    Chen, Ting
    Poteete, Alissa
    Estrada-Bernal, Adriana
    Le, Anh T.
    Truini, Anna
    Nilsson, Monique B.
    Sun, Huiying
    Roarty, Emily
    Goldberg, Sarah B.
    Brahmer, Julie R.
    Altan, Mehmet
    Lu, Charles
    Papadimitrakopoulou, Vassiliki
    Politi, Katerina
    Doebele, Robert C.
    Wong, Kwok-Kin
    Heymach, John V.
    NATURE MEDICINE, 2024, : 2694 - 2695
  • [28] Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), A Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor
    Henderson, Jaclyn L.
    Kormos, Bethany L.
    Hayward, Matthew M.
    Coffman, Karen J.
    Jasti, Jayasankar
    Kurumbail, Ravi G.
    Wager, Travis T.
    Verhoest, Patrick R.
    Noell, G. Stephen
    Chen, Yi
    Needle, Elie
    Berger, Zdenek
    Steyn, Stefanus J.
    Houle, Christopher
    Hirst, Warren D.
    Galatsis, Paul
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (01) : 419 - 432
123